A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data

Huang, Juanlan1,2; Liu, Dale2,3; Li, Jun4; Xu, Jing2,5; Dong, Shaowei4,9; Zhang, Hao6,7,8

2023-12-12

10.1080/07853890.2023.2260387

ANNALS OF MEDICINE   Impact Factor & Quartile

0785-3890

1365-2060

["Background: Castration-resistant prostate cancer (CRPC) represents one type of advanced prostate cancer (PCa) with a median survival time of 1-2 years. Currently, there is a lack of reliable gene panels in predicting hormone treatment (HT) responses due to limited knowledge of CRPC-specific tumor-microenvironment (TME) characteristics.","Methods: In this study, we first screened for up-regulated genes in CRPC samples using bulk-sequencing data retrieved from TC GA online database, and further investigated the expression status of these genes in four sets of downloaded single-cell RNA sequencing (scRNAseq) data: GSE117403 containing 16 normal human prostate samples; GSE141445 containing 13 PCa samples; GSE176031 containing 11 PCa samples and GSE137829 containing 6 CRPC samples.","Results: We identified a series of CRPC-specific TME characteristics including an enriched number of PEG10+ neuroendocrine cells, elevated expression of PPIB/CCDC74A/GAPDH/AR genes in tumor cells, increased expression of FAP/TGFB1 in cancer-associated fibroblasts (CA Fs), suppressed immune environment featured by enhanced M2 macrophage polarization, T cell exhaustion and increased number of regulatory B cells. We further established a 12-gene panel using these characteristics and showed that this panel could separate CRPC samples from PCa samples (AUC of 0.78), and CRPC patients with higher panel scores tended to have treatment failure or progression (R = -0.47, p = 0.019).","Conclusions: Based on these unique TME characteristics of CRPC, we established a prediction tool for estimating the duration of HT responses in PCa treatment. Our results suggest mechanisms by which prostate cancer becomes castrate resistant. Further study of PEG10 (and/or others) to evaluate therapeutic efficacy should be considered."]

CRPC hormone-treatment 12-gene panel combined analysis scRNAseq data

SCI

English

Others

General & Internal Medicine

Medicine, General & Internal

WOS:001067216200001

TAYLOR & FRANCIS LTD

CLINICAL MEDICINE

Web of Science

1.Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Hlth Management, Guangzhou, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Peoples R China
3.Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Urol, Guangzhou, Peoples R China
4.China Med Univ, Dept Hematol & Oncol, Shenzhen Childrens Hosp, Shenzhen, Peoples R China
5.Jinan Univ, Clin Med Coll 2, Dept Infect Dis, Shenzhen Peoples Hosp, Guangzhou, Peoples R China
6.Jinan Univ, Affiliated Hosp 1, Dept Gen Surg, Guangzhou, Peoples R China
7.Shantou Univ Med Coll, Affiliated Hosp 2, Dept Thyroid Breast & Hernia Surg, Shantou, Peoples R China
8.Jinan Univ, Affiliated Hosp 1, Dept Gen Surg, Guangzhou 513020, Guangdong, Peoples R China
9.China Med Univ, Shenzhen childrens Hosp, Dept Hematol & oncol, Shenzhen 518026, Guangdong, Peoples R China

Huang, Juanlan,Liu, Dale,Li, Jun,et al. A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data[J]. ANNALS OF MEDICINE,2023,55(2).

Huang, Juanlan,Liu, Dale,Li, Jun,Xu, Jing,Dong, Shaowei,&Zhang, Hao.(2023).A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data.ANNALS OF MEDICINE,55(2).

Huang, Juanlan,et al."A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data".ANNALS OF MEDICINE 55.2(2023).